Identifying Novel Epigenetic Dependencies in Pre-leukemic Hematopoietic Stem Cells by Haussler, Emily
Washington University in St. Louis 
Washington University Open Scholarship 
Spring 2018 Washington University Senior Honors Thesis Abstracts 
Spring 2018 
Identifying Novel Epigenetic Dependencies in Pre-leukemic 
Hematopoietic Stem Cells 
Emily Haussler 
Washington University in St. Louis 
Follow this and additional works at: https://openscholarship.wustl.edu/wushta_spr2018 
Recommended Citation 
Haussler, Emily, "Identifying Novel Epigenetic Dependencies in Pre-leukemic Hematopoietic Stem Cells" 
(2018). Spring 2018. 53. 
https://openscholarship.wustl.edu/wushta_spr2018/53 
This Abstract for College of Arts & Sciences is brought to you for free and open access by the Washington 
University 
Senior Honors Thesis Abstracts at Washington University Open Scholarship. It has been accepted for inclusion in 
Spring 2018 by an authorized administrator of Washington University Open Scholarship. For more information, 
please contact digital@wumail.wustl.edu. 
30 Spring 2018 WUSHTA
Biology
Identifying Novel Epigenetic Dependencies in 
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Mentors: Grant Challen and Elizabeth Ostrander
The DNA methylation modifying enzymes DNMT3A and TET2 are essential for proper 
differentiation of hematopoietic stem cells and are frequently found to be mutated in a 
range of blood cancers. Although their functions in regulating DNA methylation have 
been characterized, a specific connection between methylation patterns and altered 
gene expression has not been established to explain the observed disease phenotype. We 
hypothesize that DNMT3A- and TET2-mutant HSCs are dependent on other epigenetic 
regulators to corrupt normal hematopoietic pathways. If this is the case, inhibition of 
the chromatin modifiers on which driver mutations DNMT3A and TET2 depend could 
represent a novel therapeutic strategy for reducing the propagation of pre-leukemic HSC 
populations and preventing the onset of a range of blood cancers. To test this hypothesis, 
we employed a CRISPR-Cas9 based negative selection screen on cells derived from 
DNMT3A-null and TET2-null HSCs, targeting 180 chromatin modifying genes, using 
three to six sgRNA “guides” per gene. Results were obtained from three independent 
screens, and those genes showing significant fold depletion over time in DNMT3A-null 
or TET2-null cells were selected for further investigation as potential therapeutic targets. 
Specifically, Brd2 and Zmynd8 are being considered for future directions. Ultimately, 
we conclude that our negative selection CRISPR screen is optimized to detect those 
genes potentially showing an epigenetic dependence with DNMT3A and TET2 in 
hematopoiesis, and that further functional studies in vivo are needed to draw definite 
conclusions about their roles.
